Medpace (NASDAQ:MEDP) versus CochLear (OTCMKTS:CHEOY) Head to Head Review

Medpace (NASDAQ:MEDP) and CochLear (OTCMKTS:CHEOY) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Volatility and Risk

Medpace has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, CochLear has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.

Profitability

This table compares Medpace and CochLear’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medpace	17.83%	118.82%	25.07%
CochLear	N/A	N/A	N/A

Valuation & Earnings

This table compares Medpace and CochLear”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53 billion	5.16	$451.12 million	$15.30	30.08
CochLear	$1.53 billion	4.90	$251.85 million	N/A	N/A

Medpace has higher revenue and earnings than CochLear.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Medpace and CochLear, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	1	9	5	0	2.27
CochLear	0	2	1	2	3.00

Medpace presently has a consensus price target of $486.67, indicating a potential upside of 5.73%. Given Medpace’s higher possible upside, research analysts clearly believe Medpace is more favorable than CochLear.

Insider & Institutional Ownership

78.0% of Medpace shares are owned by institutional investors. 20.3% of Medpace shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Medpace beats CochLear on 11 of the 13 factors compared between the two stocks.

About Medpace

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

About CochLear

Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.